The ISSCR Comments on Public and Stakeholder Consultations for the Revision of the EU BTC Legislation

Policy
Written By Keith Alm

The ISSCR shared its comments on public and stakeholder consultations for the revision of the European Union’s (EU) legislation on blood, tissues, and cells (BTC) with the Directorate-General for Health and Food Safety
European Commission.

Comments focus on concerns regarding the premature commercialization of cellular therapies and the implications of the BTC legislation for the oversight of Advanced Therapy Medicinal Products (ATMPs).

Read the comments.

Keith Alm
Previous

Remembering Eli Broad
Next

Miniaturized Models of Neuron-Muscle Interactions Give Insight in ALS